Advertisement
Product › Details
cyclosporine (INN)
Next higher product group | interleukin 2 inhibitor | |
Status | 1993-01-01 sales existent | |
Organisation | Sandoz AG | |
Today | Novartis AG (NYSE: NVS) | |
Group | Novartis (Group) | |
Record changed: 2023-07-10 |
Advertisement
More documents for cyclosporine (INN)
- [1] Zambon Group. (7/25/19). "Press Release: Zambon Completes Transformational Acquisition of Breath Therapeutics". Milan....
- [2] Breath Therapeutics B.V.. (3/26/19). "Press Release: Breath Therapeutics Announces Initiation of Global Phase 3 Trials for the Treatment of Bronchiolitis Obliterans Syndrome". Munich & Menlo Park, CA....
- [3] Breath Therapeutics B.V.. (10/17/18). "Press Release: Breath Therapeutics Appoints Peter Shadday as Chief Commercial Officer". Munich....
- [4] Breath Therapeutics B.V.. (7/11/18). "Press Release: Breath Therapeutics Appoints Noreen Roth Henig, M.D. as Chief Medical Officer". Munich, Frankfurt & Boston, MA....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top